Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 04, 2022 at 09:05 pm
Share
Sarepta Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 210.83 million compared to USD 146.93 million a year ago. Net loss was USD 105.03 million compared to USD 167.25 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 2.1 a year ago. Diluted loss per share from continuing operations was USD 1.2 compared to USD 2.1 a year ago.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.